Charles River Laboratories
CRL
Market cap $8.72B

177.49 USD

-0.96

0.54%

Updated Jul 30, 2:05 PM EDT

1 day

-0.54%

5 days

2.30%

1 month

16.98%

3 months

49.63%

6 months

7.20%

Year to date

-2.82%

1 year

-27.64%

5 years

-11.83%

10 years

138.43%

About: Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Employees: 20,100

Healthcare Diagnostics & Research

0

Funds holding %

of 7,323 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0.01% less ownership

Funds ownership: 103.58% [Q4 2024] → 103.57% (-0.01%) [Q1 2025]

12% less funds holding

Funds holding: 628 [Q4 2024] → 553 (-75) [Q1 2025]

16% less call options, than puts

Call options by funds: $106M | Put options by funds: $125M

20% less capital invested

Capital invested by funds: $10B [Q4 2024] → $7.96B (-$2.04B) [Q1 2025]

22% less repeat investments, than reductions

Existing positions increased: 186 | Existing positions reduced: 237

47% less first-time investments, than exits

New positions opened: 71 | Existing positions closed: 133

50% less funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 2 (-2) [Q1 2025]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$140

21%

downside

Avg. target

$171

3%

downside

High target

$200

13%

upside

5 analyst ratings

3 positive

60%

2 neutral

40%

0 negative

0%

Evercore ISI Group Ross Muken	1%upside $180	Outperform Maintained	9 Jul 2025
Citigroup Patrick Donnelly	13%upside $200	Buy Upgraded	9 Jul 2025
Redburn Atlantic Jamie Clark	3%upside $182	Buy Upgraded	23 May 2025
Barclays Luke Sergott	13%downside $155	Equal-Weight Maintained	8 May 2025
Baird Eric Coldwell	21%downside $140	Neutral Maintained	8 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about CRL published over the past 30 days

Zacks Investment Research

Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?

Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?

Zacks Investment Research

Charles River Q2 Earnings Preview: What's in Store for the Stock?

CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.

Charles River Q2 Earnings Preview: What's in Store for the Stock?

Zacks Investment Research

Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?

Charles River Joins Elly's Team to Drive Rare Disease Gene Therapy Development

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--As part of Charles River's Cell & Gene Therapy Accelerator Program, Elly's Team manufactured critical starting materials for a Phase I clinical trial.

Charles River Joins Elly's Team to Drive Rare Disease Gene Therapy Development

Zacks Investment Research

Is it Prudent to Retain Charles River Stock in Your Portfolio Now?

CRL sees momentum in drug discovery and safety services, but macro pressures and currency headwinds threaten growth.

Is it Prudent to Retain Charles River Stock in Your Portfolio Now?

Proactive Investors

Creightons shares fall 10% as cautious outlook tempers improved results

Shares in Creightons PLC (LSE:CRL) dropped 10% on Wednesday despite reporting a return to profitability, as investors reacted to a cautious outlook for the year ahead. The beauty and personal care manufacturer posted a 1.6% rise in revenue to £54.1 million for the year to 31 March 2025, with strong growth in private label sales offsetting declines in branded and contract manufacturing.

Creightons shares fall 10% as cautious outlook tempers improved results

Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call.

Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call

Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River today announced a recycling program, developed in partnership with TerraCycle to give new life to single-use plastic cartridges.

Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment

Zacks Investment Research

Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report?

Zacks Investment Research

Charles River Stock May Gain From Extended CHDI Research Deal on HD

CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.

Charles River Stock May Gain From Extended CHDI Research Deal on HD

See News Rankings

Charts implemented using Lightweight Charts™